📊 MIRM Key Takeaways
Is MIRM a Good Investment? Thesis Analysis
Mirum Pharmaceuticals demonstrates strong revenue growth of 54.7% YoY with positive free cash flow generation of $54.9M, indicating operational momentum. However, the company remains unprofitable with negative net margins of -4.5% and operating losses of -$22.1M, suggesting the revenue growth has not yet translated to profitability despite scale improvements.
Why Buy MIRM? Key Strengths
- Strong topline growth of 54.7% YoY revenue increase to $521.3M demonstrates market traction
- Robust free cash flow of $54.9M (10.5% FCF margin) despite operating losses shows cash generation ability
- Excellent liquidity position with current ratio of 2.67x and $296.7M in cash equivalents provides financial flexibility
- Zero long-term debt and minimal leverage (0.00x Debt/Equity) reduces financial risk
MIRM Investment Risks to Consider
- Persistent unprofitability with operating margin of -4.2% and net margin of -4.5% raises questions about path to sustainable profitability
- Operating losses of -$22.1M despite substantial revenue suggests high operating expenses or unfavorable product mix
- Diluted EPS of -$0.47 reflects shareholder value destruction from operations, though improved 74.6% YoY
- High insider trading activity (29 Form 4 filings in 90 days) warrants monitoring for potential signal of insiders' confidence or concerns
Key Metrics to Watch
- Path to operating profitability and timeline to breakeven on operating basis
- Gross margin trends and product mix evolution to assess pricing power and cost structure
- Quarterly revenue sustainability beyond current growth rate to confirm organic demand
- Operating expense ratio as percentage of revenue to identify leverage improvements
MIRM Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.67x current ratio provides a solid financial cushion.
MIRM Profitability Ratios
MIRM vs Healthcare Sector
How Mirum Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MIRM Overvalued or Undervalued?
Based on fundamental analysis, Mirum Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MIRM Balance Sheet & Liquidity
MIRM 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Mirum Pharmaceuticals, Inc.'s revenue has grown significantly by 576% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.00 indicates the company is currently unprofitable.
MIRM Growth Metrics (YoY)
MIRM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $90.4M | $2.9M | $0.05 |
| Q2 2025 | $77.9M | -$5.9M | $-0.12 |
| Q1 2025 | $69.2M | -$14.7M | $-0.30 |
| Q3 2024 | $47.7M | -$14.2M | $-0.30 |
| Q2 2024 | $37.5M | -$24.6M | $-0.52 |
| Q1 2024 | $31.6M | -$25.3M | $-0.54 |
| Q3 2023 | $18.8M | -$23.6M | $-0.57 |
| Q2 2023 | $17.5M | -$26.9M | $-0.84 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MIRM Capital Allocation
MIRM SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Mirum Pharmaceuticals, Inc. (CIK: 0001759425)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_070311.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_070309.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_070313.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_070307.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/form4-03172026_070304.xml | View → |
❓ Frequently Asked Questions about MIRM
What is the AI rating for MIRM?
Mirum Pharmaceuticals, Inc. (MIRM) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIRM's key strengths?
Claude: Strong topline growth of 54.7% YoY revenue increase to $521.3M demonstrates market traction. Robust free cash flow of $54.9M (10.5% FCF margin) despite operating losses shows cash generation ability.
What are the risks of investing in MIRM?
Claude: Persistent unprofitability with operating margin of -4.2% and net margin of -4.5% raises questions about path to sustainable profitability. Operating losses of -$22.1M despite substantial revenue suggests high operating expenses or unfavorable product mix.
What is MIRM's revenue and growth?
Mirum Pharmaceuticals, Inc. reported revenue of $521.3M.
Does MIRM pay dividends?
Mirum Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find MIRM SEC filings?
Official SEC filings for Mirum Pharmaceuticals, Inc. (CIK: 0001759425) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIRM's EPS?
Mirum Pharmaceuticals, Inc. has a diluted EPS of $-0.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIRM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Mirum Pharmaceuticals, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIRM stock overvalued or undervalued?
Valuation metrics for MIRM: ROE of -7.4% (sector avg: 15%), net margin of -4.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIRM stock in 2026?
Our dual AI analysis gives Mirum Pharmaceuticals, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIRM's free cash flow?
Mirum Pharmaceuticals, Inc.'s operating cash flow is $55.8M, with capital expenditures of $954.0K. FCF margin is 10.5%.
How does MIRM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.5% (avg: 12%), ROE -7.4% (avg: 15%), current ratio 2.67 (avg: 2).